|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Basic and Translational Investigations |
1 Department of Pathology, New York University Medical Center, New York, NY, USA
2 Department of Neurosurgery, New York University Medical Center, New York, NY, USA
3 Department of Radiation Oncology, New York University Medical Center, New York, NY, USA
4 Department of Radiology, New York University Medical Center, New York, NY, USA
5 Department of Oncology, New York University Medical Center, New York, NY, USA
* To whom correspondence should be addressed. E-mail: ifischer{at}mdanderson.org.
 |
Abstract |
|---|
We evaluate the effects of adjuvant treatment with the angiogenesis inhibitor Avastin (bevacizumab) on pathological tissue specimens of high-grade glioma. Tissue from five patients before and after treatment with Avastin was subjected to histological evaluation and compared to four control cases of glioma before and after similar treatment protocols not including bevacizumab. Clinical and radiographic data were reviewed. Histological analysis focused on microvessel density and vascular morphology, and expression patterns of vascular endothelial growth factor-A (VEGF-A) and the hematopoietic stem cell, mesenchymal, and cell motility markers CD34, smooth muscle actin, D2-40, and fascin. All patients with a decrease in microvessel density had a radiographic response, whereas no response was seen in the patients with increased microvessel density. Vascular morphology showed apparent "normalization" after Avastin treatment in two cases, with thin-walled and evenly distributed vessels. VEGF-A expression in tumor cells was increased in two cases and decreased in three and did not correlate with treatment response. There was a trend toward a relative increase of CD34, smooth muscle actin, D2-40, and fascin immunostaining following treatment with Avastin. Specimens from four patients with recurrent malignant gliomas before and after adjuvant treatment (not including bevacizumab) had features dissimilar from our study cases. We conclude that a change in vascular morphology can be observed following anti-angiogenic treatment. There seems to be no correlation between VEGF-A expression and clinical parameters. While the phenomena we describe may not be specific to Avastin, they demonstrate the potential of tissue-based analysis for the discovery of clinically relevant treatment response biomarkers.
Key Words: angiogenesis, Avastin, bevacizumab, biomarkers, glioblastoma, glioma
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  F. M. Iwamoto, L. E. Abrey, K. Beal, P. H. Gutin, M. K. Rosenblum, V. E. Reuter, L. M. DeAngelis, and A. B. Lassman Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma Neurology, October 13, 2009; 73(15): 1200 - 1206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. L. Ebos, C. R. Lee, and R. S. Kerbel Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy Clin. Cancer Res., August 15, 2009; 15(16): 5020 - 5025. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Chi, A. G. Sorensen, R. K. Jain, and T. T. Batchelor Angiogenesis as a Therapeutic Target in Malignant Gliomas Oncologist, June 1, 2009; 14(6): 621 - 636. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Weller and W. K. A. Yung Bevacizumab -- News from the Fast Lane? Neuro-oncol, January 1, 2008; 10(5): 647 - 647. [Full Text] [PDF]
|
|
|
|
